4. What is DRDO 2 DG? How does it work? Who can take it? How to take it? Explain.
Answers
Answer:
DRDO 2-DG Medicine: The Drugs Controller General of India (DCGI) had cleared the formulation on May 1 for emergency use as an adjunct therapy in moderate to severe Covid-19 patients. Defence Minister Rajnath Singh and Health Minister Dr Harsh Vardhan on Monday (May 17) released the first batch of the indigenously developed anti-Covid-19 drug, 2-deoxy-D-glucose or ‘2-DG’.
The national drug regulator, Drugs Controller General of India (DCGI), had cleared the formulation on May 1 for emergency use as an adjunct therapy in moderate to severe Covid-19 patients.
Explanation:
2-DG has been developed by the Institute of Nuclear Medicine and Allied Sciences (INMAS), New Delhi, a lab of the Defence Research and Development Organisation (DRDO), in collaboration with Hyderabad-based pharma company Dr Reddy’s Laboratories (DRL), the Ministry of Defence had said in a release earlier this month. According to the government release, clinical trial data show that the molecule helps in faster recovery of patients hospitalised with Covid-19, and reduces their dependence on supplemental oxygen. The drug accumulates in virus-infected cells, and prevents the growth of the virus by stopping viral synthesis and energy production. Its selective accumulation in virally-infected cells makes this drug unique, the release said.